Airlevo Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Levosalbutamol tartrate

Indications/Uses

Treatment or prevention of bronchospasm in adults w/ reversible obstructive airway disease.

Click to view Airlevo detailed prescribing information

Dosage/Direction for Use

Adult 2 inhalations (levosalbutamol free base 90 mcg) repeated every 4-6 hr; in some patients, 1 inhalation (levosalbutamol free base 45 mcg) every 4 hr may be sufficient.

Click to view Airlevo detailed prescribing information

Overdosage

View Airlevo overdosage for action to be taken in the event of an overdose.

Contraindications

History of hypersensitivity to levosalbutamol or racemic salbutamol (reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis & oropharyngeal edema).

Click to view Airlevo detailed prescribing information

Special Precautions

For oral inhalation only. Avoid spraying in the eyes. Discontinue immediately if paradoxical bronchospasm or significant CV effects occur. Deterioration of asthma. Use of β-adrenergic agonist alone may not be adequate to control asthma, give early consideration to adding anti-inflammatory agents eg, corticosteroids, to therapeutic regimen. May produce ECG changes eg, flattening of T-wave, prolongation of QTc interval, & ST segment depression. Do not exceed recommended dose. Immediate hypersensitivity reactions. Patients w/ CV disorders, especially coronary insufficiency, HTN, & cardiac arrhythmias; convulsive disorders, hyperthyroidism, or DM; & who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic & diastolic BP after use of any β-adrenergic bronchodilator. Large doses of IV racemic salbutamol may aggravate preexisting DM & ketoacidosis. Hypokalemia. May affect ability to drive & use machines. Renal impairment. Pregnancy & lactation. Elderly.

Click to view Airlevo detailed prescribing information

Use In Pregnancy & Lactation

Click to view Airlevo detailed prescribing information

Adverse Reactions

Paradoxical bronchospasm, CV effects, immediate hypersensitivity reactions, hypokalemia. Cough; tremor.

Click to view Airlevo detailed prescribing information

Drug Interactions

Do not use concomitantly w/ other short-acting sympathomimetic aerosol bronchodilators or epinephrine. Block pulmonary effect & produce severe bronchospasm in asthmatic patients w/ β-blockers. Acutely worsened ECG changes or hypokalemia w/ non-K sparing diuretics (eg, loop & thiazide diuretics). Mean decreases in serum digoxin levels after single-dose IV & PO of racemic salbutamol. Action of salbutamol on vascular system may be potentiated w/ MAOIs or TCAs, or w/in 2 wk of discontinuation of such agents.

Click to view Airlevo detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Airlevo detailed prescribing information

Storage

View Airlevo storage conditions for details to ensure optimal shelf-life.

Description

View Airlevo description for details of the chemical structure and excipients (inactive components).

Action

View Airlevo mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03AC - Selective beta-2-adrenoreceptor agonists ; Used in the treatment of obstructive airway diseases.

Regulatory Classification

Patient Counseling Information

View Airlevo patient counselling information

Presentation/Packing

Form

Airlevo inhalation aerosol 45 mcg/actuation

Packing/Price

(with metered valve) 200 actuation x 1's (P450/canister)

Airlevo

Manufacturer:

Glenmark

Distributor:

Glenmark